CDK1-IN-2

• CAT Number: R066974
• CAS Number: 220749-41-7
• Molecular Formula: C17H11ClN2O
• Molecular Weight: 294.74
• Purity: ≥95%
• Synonyms: (3E)-3-[(2-chloro-1H-indol-3-yl)methylidene]-1H-indol-2-one
• IUPAC Name: 3-[(2-chloro-1H-indol-3-yl)methylidene]-1H-indol-2-one
• InChI: InChI=1S/C17H11ClN2O/c18-16-12(10-5-1-3-7-14(10)19-16)9-13-11-6-2-4-8-15(11)20-17(13)21/h1-9,19H,(H,20,21)
• InChIKey: QJKBRWSJWQVKLY-UHFFFAOYSA-N
• SMILES: C1=CC=C2C(=C1)C(=CC3=C(NC4=CC=CC=C43)Cl)C(=O)N2

CDK1-IN-2（Cat No.:R066974）is a selective small molecule inhibitor targeting cyclin-dependent kinase 1 (CDK1), a key regulator of the cell cycle, particularly during mitosis. By inhibiting CDK1, CDK1-IN-2 interferes with cell cycle progression, leading to cell cycle arrest and potentially inducing apoptosis in rapidly proliferating cancer cells. It is being investigated as a potential therapeutic agent in cancer treatment, especially for tumors with dysregulated cell cycle control. Preclinical studies have shown promising results, and ongoing research is focused on evaluating its efficacy, safety, and potential for use in combination therapies to enhance cancer treatment outcomes.